Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics announced that it has executed a contract manufacturing agreement worth approximately KRW 119.1B with a pharmaceutical company based in Asia.
📊 [Key Disclosure Details & Summary Statistics]
- Contract Classification: Sales/Supply Contract (Contract Manufacturing Agreement for Pharmaceutical Products)
- Contract Amount: KRW 119,112,745,680 (KRW ~119.1B) / USD 88,916,651
- Recent Annual Revenue: KRW 3,694,588,767,068 (Based on 2023 consolidated financial statements)
- Contract Ratio to Revenue: 3.22%
- Large Corporation Status: Applicable
- Counterparty: Pharmaceutical company located in Asia
- Contract Period: June 2, 2023 – December 31, 2028
- Contract (Order) Date: September 13, 2024
- Non-disclosure of Counterparty Details:
- Postponement Period for Counterparty Disclosure: Until December 31, 2028 (Due to business trade secrecy)
- Other Key Investment Matters:
- The contract amount was converted using the initial standard FX rate of USD/KRW 1,339.60 on September 13, 2024, based on the confirmed amount of USD 88,916,651.
- The initial agreement on June 2, 2023, fell below the mandatory disclosure threshold; however, an amendment to the contract increased the value, triggering this new disclosure.
- The contract end date is subject to change based on mutual agreement between both parties.
- The scheduled counterparty disclosure date is subject to change in the future.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Contract Revisions and Order Backlog Status in Periodic Reports
This disclosure was triggered after an amendment increased the contract value above the mandatory public disclosure threshold. Tracking potential changes to contract terms—such as revisions to the contract amount, end date, or FX adjustments—is important for understanding how the contract contributes to revenue over the agreement period. Relevant updates and overall order details can be verified in subsequent disclosures or periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided strictly for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
